Related Experiment Video

Updated: Mar 5, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.3K

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential

Sara Pusceddu1, Elena Verzoni1, Natialie Prinzi1

  • 1Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.

Therapeutic Advances in Medical Oncology
|March 28, 2017
PubMed

Insights

Everolimus effectively treats neuroendocrine tumors (NETs) by inhibiting the PI3K/AKT/mTOR pathway. Clinical trials confirm its efficacy and safety, establishing its role in NET management.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Neuroendocrine tumors (NETs) present complex management challenges.
  • The PI3K/AKT/mTOR signaling pathway is implicated in NET pathogenesis and progression.
  • Everolimus, a direct inhibitor of this pathway, is a promising therapeutic strategy for NETs.

Purpose of the Study:

  • To review the efficacy and safety of everolimus in treating NETs.
  • To discuss the current clinical role of everolimus based on RADIANT trials and other evidence.

Main Methods:

  • Review of published clinical trial data, focusing on the RADIANT trials.
  • Analysis of evidence regarding everolimus's impact on NET treatment.

Main Results:

  • The RADIANT trials demonstrated the efficacy and safety of everolimus in NET treatment.
  • Everolimus shows potential to alter clinical practice for NET management.

Conclusions:

  • Everolimus is a validated therapeutic option for neuroendocrine tumors.
  • Current evidence supports the use of everolimus in the management of NETs.
Keywords:
RADIANT trialseverolimusneuroendocrine tumors

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.5K
Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics08:43

Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics

Published on: November 30, 2012

20.8K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
517
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
698
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K